Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Diabetes Metab Syndr ; 15(5): 102235, 2021.
Article in English | MEDLINE | ID: covidwho-1330757

ABSTRACT

BACKGROUND AND AIMS: Post Covid-19 syndrome (PCS) is a major cause of morbidity. In this article we intend to review the association and consequences of PCS and diabetes. METHODS: We reviewed all studies on "Long Covid", "Post COVID-19 Syndrome" and diabetes in PubMed and Google Scholar. RESULTS: The symptoms of PCS can be due to organ dysfunction, effects of hospitalisation and drugs, or unrelated to these. Type 2 diabetes mellitus has a bidirectional relationship with COVID-19. Presence of diabetes also influences PCS via various pathophysiological mechanisms. COVID-19 can add to or exacerbate tachycardia, sarcopenia (and muscle fatigue), and microvascular dysfunction (and organ damage) in patients with diabetes. CONCLUSION: PCS in patients with diabetes could be detrimental in multiple ways. Strict control of diabetes and other comorbidities, supervised rehabilitation and physical exercise, and optimal nutrition could help in reducing and managing PCS.


Subject(s)
COVID-19/complications , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/etiology , COVID-19/therapy , Comorbidity , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/therapy , Fatigue/diagnosis , Fatigue/epidemiology , Fatigue/etiology , Fatigue/therapy , Humans , SARS-CoV-2/physiology , Sarcopenia/diagnosis , Sarcopenia/epidemiology , Sarcopenia/etiology , Sarcopenia/therapy , Tachycardia/diagnosis , Tachycardia/epidemiology , Tachycardia/etiology , Tachycardia/therapy
2.
BMJ Case Rep ; 13(9)2020 Sep 08.
Article in English | MEDLINE | ID: covidwho-828187

ABSTRACT

This case aims to remind all providers to scrutinise for atypical presentations of multisystem inflammatory syndrome in children (MIS-C) which may mimic a more routine diagnosis. In the absence of mucocutaneous symptoms, the diagnosis of MIS-C can be missed. Given the potential for rapid deterioration of patients with MIS-C, early treatment and inpatient interventions are necessary.


Subject(s)
Abdominal Pain/immunology , COVID-19/diagnosis , Fever/immunology , SARS-CoV-2/isolation & purification , Systemic Inflammatory Response Syndrome/diagnosis , Tachycardia/immunology , Abdominal Pain/blood , Abdominal Pain/therapy , Abdominal Pain/virology , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Alanine/analogs & derivatives , Alanine/therapeutic use , C-Reactive Protein/analysis , COVID-19/blood , COVID-19/drug therapy , COVID-19/immunology , COVID-19/therapy , COVID-19 Nucleic Acid Testing , COVID-19 Serological Testing , Child , Diagnosis, Differential , Fever/blood , Fever/therapy , Fever/virology , Humans , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Intubation, Intratracheal , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Myocarditis/diagnosis , Nasopharynx/virology , Natriuretic Peptide, Brain/blood , SARS-CoV-2/immunology , Systemic Inflammatory Response Syndrome/blood , Systemic Inflammatory Response Syndrome/immunology , Systemic Inflammatory Response Syndrome/therapy , Tachycardia/blood , Tachycardia/therapy , Tachycardia/virology , Treatment Outcome
3.
Clin Microbiol Infect ; 27(1): 89-95, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-803353

ABSTRACT

OBJECTIVES: To describe the prevalence, nature and risk factors for the main clinical sequelae in coronavirus disease 2019 (COVID-19) survivors who have been discharged from the hospital for more than 3 months. METHODS: This longitudinal study was based on a telephone follow-up survey of COVID-19 patients hospitalized and discharged from Renmin Hospital of Wuhan University, Wuhan, China before 1 March 2020. Demographic and clinical characteristics and self-reported clinical sequelae of the survivors were described and analysed. A cohort of volunteers who were free of COVID-19 and lived in the urban area of Wuhan during the outbreak were also selected as the comparison group. RESULTS: Among 538 survivors (293, 54.5% female), the median (interquartile range) age was 52.0 (41.0-62.0) years, and the time from discharge from hospital to first follow-up was 97.0 (95.0-102.0) days. Clinical sequelae were common, including general symptoms (n = 267, 49.6%), respiratory symptoms (n = 210, 39%), cardiovascular-related symptoms (n = 70, 13%), psychosocial symptoms (n = 122, 22.7%) and alopecia (n = 154, 28.6%). We found that physical decline/fatigue (p < 0.01), postactivity polypnoea (p= 0.04) and alopecia (p < 0.01) were more common in female than in male subjects. Dyspnoea during hospitalization was associated with subsequent physical decline/fatigue, postactivity polypnoea and resting heart rate increases but not specifically with alopecia. A history of asthma during hospitalization was associated with subsequent postactivity polypnoea sequela. A history of pulse ≥90 bpm during hospitalization was associated with resting heart rate increase in convalescence. The duration of virus shedding after COVID-19 onset and hospital length of stay were longer in survivors with physical decline/fatigue or postactivity polypnoea than in those without. CONCLUSIONS: Clinical sequelae during early COVID-19 convalescence were common; some of these sequelae might be related to gender, age and clinical characteristics during hospitalization.


Subject(s)
Alopecia/epidemiology , COVID-19/epidemiology , Dyspnea/epidemiology , Fatigue/epidemiology , Survivors , Tachycardia/epidemiology , Adult , Alopecia/complications , Alopecia/physiopathology , Alopecia/therapy , COVID-19/complications , COVID-19/physiopathology , COVID-19/therapy , China/epidemiology , Convalescence , Dyspnea/complications , Dyspnea/physiopathology , Dyspnea/therapy , Fatigue/complications , Fatigue/physiopathology , Fatigue/therapy , Female , Humans , Length of Stay/statistics & numerical data , Longitudinal Studies , Male , Middle Aged , Patient Discharge , Risk Factors , SARS-CoV-2/pathogenicity , Severity of Illness Index , Tachycardia/complications , Tachycardia/physiopathology , Tachycardia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL